Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

What is the Role of Transplant in Managing Patients With Myelofibrosis?

January 19th 2023

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD

January 18th 2023

First-line ibrutinib plus prednisone did not improve response rates compared with placebo plus prednisone in patients with chronic graft-vs-host disease, failing to meet the primary end point of the phase 3 iNTEGRATE trial.

Tools for Risk Stratification and Prognosis in MDS

January 18th 2023

Uwe Platzbecker, MD introduces models commonly used to determine risk status and prognosis, and inform treatment decisions, for patients with MDS.

NCCN Adds Olutasidenib to Guidelines for Relapsed/Refractory, IDH1-Mutant AML

January 18th 2023

Olutasidenib has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a recommended targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia with an IDH1 mutation.

MDS: Typical Patient Presentation, Diagnostic Process, and Evolving Terminology

January 18th 2023

Moderator Rami Komrokji, MD, introduces the panel and invites expert pathologist Sanam Loghavi, MD to lead a discussion on the typical patient presentation and diagnostic process in MDS, which was recently renamed as ‘myelodysplastic neoplasms’ in the 2022 5th edition of the World Health Organization (WHO) classification of the disease state.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Shining a Light on the MASTER Trial Evaluating D-KRd

January 18th 2023

In this second episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, discusses the depth of response reported with daratumumab, carfilzomib, lenalidomide, and dexamethasone in transplant-eligible multiple myeloma.

Identification of Tumor Lysis Syndrome: Signs and Symptoms

January 18th 2023

Comprehensive insight on the signs and symptoms that help lead to the identification of tumor lysis syndrome in patients receiving therapy for cancer.

Overview on Tumor Lysis Syndrome: Incidence and Risk Factors

January 18th 2023

Key opinion leaders James Short, MD, and John Reagan, MD, share an overview on the incidence and clinical risk factors of tumor lysis syndrome.

IPSS-M and IPSS-R Tools for Risk Stratification of MDS

January 18th 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, compare the available IPSS-M and IPSS-R tools for stratifying risk and assessing prognosis in MDS.

Classification Systems for MDS

January 18th 2023

Distinguished experts in hematology discuss the WHO and ICC classification systems for myelodysplastic syndromes (MDS), including recent WHO updates.

FDA Grants Orphan Drug Designation to JBI-802 for Small Cell Lung Cancer and AML

January 16th 2023

The FDA has granted an orphan drug designation to JBI-802 for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

Axi-cel Maintains PFS and ORR Benefit in 3-Year Follow-Up of ZUMA-5 in Indolent NHL

January 16th 2023

Axicabtagene ciloleucel continued to elicit improved progression-free survival and overall response rates in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Zanubrutinib Extends Treatment Duration in Acalabrutinib-Intolerant Patients With B-cell Malignancies

January 16th 2023

Patients with B-cell malignancies who were intolerant to acalabrutinib experienced a longer treatment duration when subsequently receiving zanubrutinib.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Examining Findings From the GRIFFIN Trial of D-RVd

January 13th 2023

In this first episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, provides perspective on the use of daratumumab-based quadruplets as induction therapy in multiple myeloma.

Teclistamab Plus Daratumumab/Lenalidomide Generates Responses in Relapsed/Refractory Myeloma

January 13th 2023

Emma Searle, PhD, provides an overview of findings from the MajesTEC-2 trial in patients with relapsed/refractory multiple myeloma, elaborates on the safety of teclistamab plus daratumumab and lenalidomide, and discusses the next steps for evaluating the combination.

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13th 2023

Moxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.

Regimens Used for GvHD Prevention

January 13th 2023

A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.

An Overview of Graft vs Host Disease (GvHD)

January 13th 2023

Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.

Therapy in Myelofibrosis: Fedratinib and Ruxolitinib Strategies

January 12th 2023

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m Newly Diagnosed AML Treated with IVO + AZA in the AGILE Study

January 12th 2023

Pau Montesinos, MD discusses key updates from the global phase 3 AGILE study, as presented at the 2022 American Society of Hematology Annual Meeting, and speaks to the clinical implications of these data.